Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
•
Primary Care
Would you recommend patients with newly diagnosed bladder cancer to discontinue SGLT2 inhibitors?
Related Questions
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
For neoadjuvant treatment of muscle invasive bladder cancer, are you utilizing durvalumab plus gemcitabine cisplatin over dose dense or accelerated MVAC?
Are there scenarios where you would still prefer adjuvant nivolumab based on known pathologic risk over using perioperative durvalumab for all patients with muscle invasive bladder cancer?
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
How do you decide between internal versus external decompression of malignant obstruction of the ureter (MUO)?
What are your top takeaways in GU Cancers from ESMO 2024?
How do you interpret NIAGARA efficacy given that adjuvant nivolumab was not administered in the comparator arm?
Would you consider omitting adjuvant durvalumab in MIBC to limit overtreatment in patients who may not benefit or those who have achieved maximal benefit after neoadjuvant gem/cis/durva?
Are you dose reducing/omitting IV dexamethasone as a pre-medication for anti-emesis in patients with MIBC when using durvalumab/gemcitabine/cisplatin?
In patients with muscle-invasive bladder cancer seeking bladder preservation, would positive ctDNA affect your approach to trimodality therapy?
